» Articles » PMID: 20138505

Does Delaying Adjuvant Chemotherapy After Curative Surgery for Colorectal Cancer Impair Survival? A Meta-analysis

Overview
Journal Eur J Cancer
Specialty Oncology
Date 2010 Feb 9
PMID 20138505
Citations 104
Authors
Affiliations
Soon will be listed here.
Abstract

Background: In stage III colorectal cancer (CRC), adjuvant chemotherapy (CT) is usually prescribed within two months after curative surgery. Whether or not delaying initiation of CT affects survival is still debated.

Material And Methods: We performed a meta-analysis (MA) of all published studies (full papers or abstracts) comparing delayed CT with standard care. Studies were obtained from a PubMed query (keywords: CRC, adjuvant treatment, delay of CT), a review (Chau et al., 2006), cross-checking references and abstracts from the proceedings of ASCO, ASCO GI and WCGI annual meetings. We chose a cutoff delay of 8 weeks. Risk Ratios (RRs) were calculated from the recorded events (deaths, relapses). We used EasyMA software (fixed-effect model).

Results: Fourteen studies (including four abstracts) were identified (17,645 patients; 5,952 males, 5,151 females, mean age 70 years). Of these, three could not be statistically analysed and three used another cutoff (4, 5 or 6 weeks), leaving 8 studies for main MA (13,158 patients; 3,932 males, 3,644 females, 5,942 missing data; 5,576 colon cancers, 6,677 rectal, 1,265 missing data). Delaying CT more than 8 weeks was associated to worse Overall Survival (OS) (RR: 1.20; 95% Confidence Interval (CI) 1.15-1.26). In the MA including all studies whatever their cutoff, longer delay was similarly associated to a worse OS but not a worse Relapse-Free Survival (RFS) (five studies).

Conclusion: Adjuvant chemotherapy should be started within 8 weeks after surgery. Delaying the initiation of adjuvant CT for more than 8 weeks after surgery significantly decreased OS but not RFS. This discrepancy might be due to factors not directly related to cancer (post-operative complications, social status) or to a more accurate appraisal of death.

Citing Articles

The role of adjuvant chemotherapy in rectal cancer: A nationwide cohort study from the Netherlands.

Darai A, Koeter T, van Erning F, van Alphen R, Verheul H, Verheij M Colorectal Dis. 2025; 27(3):e70054.

PMID: 40059308 PMC: 11891379. DOI: 10.1111/codi.70054.


The impact of postoperative recurrent postoperative ileus on the prognosis of colorectal cancer: a propensity score matched study.

Xie R, Qiu C, Lai R, Que Z, Lin S, Xu D Updates Surg. 2025; .

PMID: 40057926 DOI: 10.1007/s13304-025-02142-z.


Socioeconomic and geographic variation in adjuvant chemotherapy among elderly patients with stage III colon cancer in Norway - a national register-based cohort study.

Gustavsen E, Norderval S, Dorum L, Balto A, Heimdal R, Vonen B Res Health Serv Reg. 2024; 3(1):21.

PMID: 39688645 PMC: 11652436. DOI: 10.1007/s43999-024-00057-7.


Predicting disease-free survival in locally advanced rectal cancer using a prognostic model based on pretreatment b-value threshold map and postoperative pathologic features.

Chen F, Zhang S, Fu C, Grimm R, Lu J, Shao C Jpn J Radiol. 2024; 43(2):236-246.

PMID: 39432017 DOI: 10.1007/s11604-024-01674-5.


Racial comparisons in treatment of rectal adenocarcinoma and survival in the military health system.

Eaglehouse Y, Darmon S, Gage M, Shriver C, Zhu K JNCI Cancer Spectr. 2024; 8(5).

PMID: 39208282 PMC: 11413531. DOI: 10.1093/jncics/pkae074.